All In MedTech

Device Trial Radar · NCT07809022

Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery

Temporary Tear Duct Filling With Hyaluronic Acid Gel and Assessment of Dry Eye Disease (DED) After Bilateral Cataract Surgery in a Prospective Randomized Controlled Inter-eye Study

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

25

Planned (sponsor's estimate)

Start

Sep 15, 2026

Primary completion

Oct 1, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Medical University of ViennaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 9, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 45 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Dry eye disease can occur or worsen after cataract surgery and may cause ocular discomfort and reduced visual quality. Standard treatment commonly includes artificial tear eye drops, which provide temporary lubrication. Temporary occlusion of the tear drainage system may offer an alternative approach by increasing tear retention and improving tear film stability. This prospective, randomized, double-blind, inter-eye study will evaluate the use of LACRIFILL® Canalicular Gel, a crosslinked hyaluronic acid gel placed in the tear drainage system, in patients who have undergone bilateral cataract surgery. Treatment allocation will be randomized at the eye level within each participant. One eye will be assigned to treatment with LACRIFILL®, while the fellow eye will serve as the control and receive standard care with artificial tear eye drops. The study will compare the development and severity of dry eye disease between the randomized treatment and control eyes. The main outcome will be tear production measured by the Schirmer Test 1 one month after treatment. Additional assessments will include tear film stability, ocular surface findings, anterior segment imaging, visual quality, dry eye symptoms, use of artificial tears, and treatment-related safety outcomes during a three-month follow-up period.

Conditions

  • Dry Eye
  • Dry Eye Disease (DED)
  • Dry Eye Sensation After Cataract Surgery

Interventions

  • LACRIFILL® Canalicular Gel administrationDevice

    LACRIFILL® Canalicular Gel is a crosslinked hyaluronic acid hydrogel administered intracanalicularly into the lower canaliculus. Approximately 0.2 mL is administered as a single application to the randomized treatment eye to achieve temporary occlusion of the lacrimal drainage system.

  • Sham lacrimal canalicular procedureProcedure

    Lacrimal irrigation performed as a sham procedure in the control eye without administration of LACRIFILL® Canalicular Gel or temporary canalicular occlusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Inter-eye difference in Schirmer Test 1 at month 1Time frame: 1 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Medical University of Vienna, Department of Ophthalmology and Optometry

    Vienna, State of Vienna, Austria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.